Public-registry site landscape for NCT04227106, a Epidermolysis Bullosa study sponsored by Abeona Therapeutics, Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04227106 (registry record) |
| Sponsor | Abeona Therapeutics, Inc |
| Condition(s) | Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa |
| Phase | PHASE3 |
| Listed sites | 2 |
| Site countries | United States |
Eichor generates a preliminary site-risk snapshot for NCT04227106 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →